Drug Topics June 24, 2025
In a real-world, 6-month analysis, glucagon-like peptide-1 programs with obesity telemedicine behavioral programs resulted in benefits to weight loss and blood pressure.
In a 6-month real-world program, obesity telemedicine that combined glucagon-like peptide-1 (GLP-1) receptor agonists and WeightWatchers Clinic, a behavioral program as a companion to GLP-1s, showed significant declines in weight and blood pressure, which is consistent with randomized controlled trials.1
In a study published in Obesity, investigators found that telehealth obesity programs demonstrated outcomes consistent with phase 3 trials of antiobesity medications and WeightWatchers Clinic. Investigators found that average weight loss was 8.9% at 3 months, 14.1% at 6 months, 17.7% at 9 months, and 19.4% at 12 months.2
In the new study presented as a poster at...
Today's Sponsors
Today's Sponsor